Filtered By:
Source: The Lancet Neurology
This page shows you your search results in order of date. This is page number 11.
Order by Relevance | Date
Total 249 results found since Jan 2013.
Increasing value and reducing waste in stroke research
Publication date: May 2017 Source:The Lancet Neurology, Volume 16, Issue 5 Author(s): Eivind Berge, Rustam Al-Shahi Salman, H Bart van der Worp, Christian Stapf, Peter Sandercock, Nikola Sprigg, Malcolm R Macleod, Peter J Kelly, Paul J Nederkoorn, Gary A Ford Stroke is a major burden to patients and society, and resources spent on stroke research must be used efficiently and produce good value in terms of improvements in human health. However, many instances of poor value from stroke research funding have resulted from the way in which stroke research topics have been chosen and how studies have been designed, conducted, ...
Source: The Lancet Neurology - April 12, 2017 Category: Neurology Source Type: research
Can allogeneic stem cells improve outcomes after stroke?
Publication date: Available online 17 March 2017 Source:The Lancet Neurology Author(s): Steven C Cramer
Source: The Lancet Neurology - March 17, 2017 Category: Neurology Source Type: research
Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial
This study is registered with ClinicalTrials.gov, number NCT01436487. Findings The study was done between Oct 24, 2011, and Dec 7, 2015. After safety assessments in eight patients in group 1, 129 patients were randomly assigned (67 to receive multipotent adult progenitor cells and 62 to receive placebo) in groups 2 and 3 (1200 million cells). The ITT populations consisted of 65 patients who received multipotent adult progenitor cells and 61 patients who received placebo. There were no dose-limiting toxicity events in either group. There were no infusional or allergic reactions and no difference in treatment-emergent advers...
Source: The Lancet Neurology - March 17, 2017 Category: Neurology Source Type: research
Safety and efficacy of thrombectomy in acute ischaemic stroke (REVASCAT): 1-year follow-up of a randomised open-label trial
We report the results of the prespecified 12-month analysis of the REVASCAT trial. Methods Patients with acute ischaemic stroke who could be treated within 8 h of symptom onset were randomly assigned to medical therapy (including intravenous alteplase when eligible) and neurovascular thrombectomy with Solitaire FR or medical therapy alone. The main secondary outcome measure at 1 year follow-up was disability, measured using the modified Rankin Scale (mRS), ranging from 0 (no symptoms) to 6 (death) with categories 5 (severe disability) and 6 (death) collapsed into one category (severe disability or death), analysed as the d...
Source: The Lancet Neurology - March 16, 2017 Category: Neurology Source Type: research
The cause of stroke matters for secondary prevention
Publication date: April 2017 Source:The Lancet Neurology, Volume 16, Issue 4 Author(s): Hans-Christoph Diener
Source: The Lancet Neurology - March 14, 2017 Category: Neurology Source Type: research
Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial
Publication date: Available online 23 February 2017 Source:The Lancet Neurology Author(s): Pierre Amarenco, Gregory W Albers, Hans Denison, J Donald Easton, Scott R Evans, Peter Held, Michael D Hill, Jenny Jonasson, Scott E Kasner, Per Ladenvall, Kazuo Minematsu, Carlos A Molina, Yongjun Wang, K S Lawrence Wong, S Claiborne Johnston Background Ticagrelor is an effective antiplatelet therapy for patients with coronary atherosclerotic disease and might be more effective than aspirin in preventing recurrent stroke and cardiovascular events in patients with acute cerebral ischaemia of atherosclerotic origin. Our aim was to te...
Source: The Lancet Neurology - February 23, 2017 Category: Neurology Source Type: research
Can natalizumab be beneficial in acute ischaemic stroke?
Publication date: March 2017 Source:The Lancet Neurology, Volume 16, Issue 3 Author(s): Turgut Tatlisumak
Source: The Lancet Neurology - February 15, 2017 Category: Neurology Source Type: research
Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial
Publication date: March 2017 Source:The Lancet Neurology, Volume 16, Issue 3 Author(s): Jacob Elkins, Roland Veltkamp, Joan Montaner, S Claiborne Johnston, Aneesh B Singhal, Kyra Becker, Maarten G Lansberg, Weihua Tang, Ih Chang, Kumar Muralidharan, Sarah Gheuens, Lahar Mehta, Mitchell S V Elkind Background In animal models of acute ischaemic stroke, blocking of the leukocyte-endothelium adhesion by antagonism of α4 integrin reduces infarct volumes and improves outcomes. We assessed the effect of one dose of natalizumab, an antibody against the leukocyte adhesion molecule α4 integrin, in patients with acute ischaemic st...
Source: The Lancet Neurology - February 15, 2017 Category: Neurology Source Type: research
Mobile stroke units for prehospital thrombolysis, triage, and beyond: benefits and challenges
Publication date: March 2017 Source:The Lancet Neurology, Volume 16, Issue 3 Author(s): Klaus Fassbender, James C Grotta, Silke Walter, Iris Q Grunwald, Andreas Ragoschke-Schumm, Jeffrey L Saver In acute stroke management, time is brain. Bringing swift treatment to the patient, instead of the conventional approach of awaiting the patient's arrival at the hospital for treatment, is a potential strategy to improve clinical outcomes after stroke. This strategy is based on the use of an ambulance (mobile stroke unit) equipped with an imaging system, a point-of-care laboratory, a telemedicine connection to the hospital, and ap...
Source: The Lancet Neurology - February 15, 2017 Category: Neurology Source Type: research
Holter-electrocardiogram-monitoring in patients with acute ischaemic stroke (Find-AFRANDOMISED): an open-label randomised controlled trial
Publication date: Available online 8 February 2017 Source:The Lancet Neurology Author(s): Rolf Wachter, Klaus Gröschel, Götz Gelbrich, Gerhard F Hamann, Pawel Kermer, Jan Liman, Joachim Seegers, Katrin Wasser, Anna Schulte, Falko Jürries, Anna Messerschmid, Nico Behnke, Sonja Gröschel, Timo Uphaus, Anne Grings, Tugba Ibis, Sven Klimpe, Michaela Wagner-Heck, Magdalena Arnold, Evgeny Protsenko, Peter U Heuschmann, David Conen, Mark Weber-Krüger Background Atrial fibrillation is a major risk factor for recurrent ischaemic stroke, but often remains undiagnosed in patients who have had an acute ischaemic stroke. Enhanced ...
Source: The Lancet Neurology - February 7, 2017 Category: Neurology Source Type: research
The relevance of atrial fibrillation in stroke prevention
Publication date: Available online 8 February 2017 Source:The Lancet Neurology Author(s): Fernando D Testai
Source: The Lancet Neurology - February 7, 2017 Category: Neurology Source Type: research
Mechanical thrombectomy after intravenous thrombolysis for acute ischaemic stroke
Publication date: February 2017 Source:The Lancet Neurology, Volume 16, Issue 2 Author(s): Jetan H Badhiwala, Farshad Nassiri, Abhaya V Kulkarni, Julian Spears, Saleh A Almenawer
Source: The Lancet Neurology - January 12, 2017 Category: Neurology Source Type: research
Mechanical thrombectomy after intravenous thrombolysis for acute ischaemic stroke – Authors' reply
Publication date: February 2017 Source:The Lancet Neurology, Volume 16, Issue 2 Author(s): Serge Bracard, Xavier Ducrocq, Francis Guillemin, Thierry Moulin, Jean-Louis Mas
Source: The Lancet Neurology - January 12, 2017 Category: Neurology Source Type: research
Ultra-rare genetic variation in common epilepsies: a case-control sequencing study
Publication date: February 2017 Source:The Lancet Neurology, Volume 16, Issue 2 Author(s): Epi4K consortiumEpilepsy Phenome/Genome Project Background Despite progress in understanding the genetics of rare epilepsies, the more common epilepsies have proven less amenable to traditional gene-discovery analyses. We aimed to assess the contribution of ultra-rare genetic variation to common epilepsies. Methods We did a case-control sequencing study with exome sequence data from unrelated individuals clinically evaluated for one of the two most common epilepsy syndromes: familial genetic generalised epilepsy, or familial or spor...
Source: The Lancet Neurology - January 12, 2017 Category: Neurology Source Type: research
Greg Albers: changing the face of the stroke stopwatch
Publication date: Available online 6 January 2017 Source:The Lancet Neurology Author(s): Jules Morgan
Source: The Lancet Neurology - January 5, 2017 Category: Neurology Source Type: research
